# Carol Aghajanian

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/carol-aghajanian/

## Facts

| Field | Value |
| --- | --- |
| Citations | 36,910 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 89 |
| i10-index | 330 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5054602117 |
| ORCID iD | 0000-0003-0851-3225 |
| Works | 844 |

## Researcher papers

Showing 12 of 18.

- [Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer](https://scholariq.org/papers/maintenance-olaparib-in-patients-with-newly-diagnosed-advanced-ovarian-cancer/)
- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer](https://scholariq.org/papers/oceans-a-randomized-double-blind-placebo-controlled-phase-iii-trial-of/)
- [Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer](https://scholariq.org/papers/veliparib-with-first-line-chemotherapy-and-as-maintenance-therapy-in-ovarian/)
- [Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer](https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-in-advanced-endometrial-cancer/)
- [Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial](https://scholariq.org/papers/gemcitabine-and-docetaxel-in-patients-with-unresectable-leiomyosarcoma-results/)
- [Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients](https://scholariq.org/papers/genomic-characterization-of-metastatic-patterns-from-prospective-clinical/)
- [Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm](https://scholariq.org/papers/improved-progression-free-and-overall-survival-in-advanced-ovarian-cancer-as-a/)
- [Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-in-patients-with-advanced-endometrial-cancer/)
- [Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/final-overall-survival-of-a-randomized-trial-of-bevacizumab-for-primary/)
- [Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial](https://scholariq.org/papers/overall-survival-with-maintenance-olaparib-at-a-7-year-follow-up-in-patients/)
- [Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-ii-trial-of-bevacizumab-in-recurrent-or-persistent-endometrial-cancer-a/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [BRCA gene mutations in cancer](https://scholariq.org/topics/brca-gene-mutations-in-cancer/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.